Kopran Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 16, 2026
- Posted by: Kunal Singla
- Category: News
The Kopran share price target 2026 is Rs 220, implying approximately 20 percent upside from the current market price of Rs 183.38 (NSE: KOPRAN-BE). With Q4 FY26 results released in 2026 and Pharmaceutical APIs and Formulations tailwinds in focus, the Rs 220 price objective is supported by the FY27 earnings recovery thesis.
Kopran (NSE: KOPRAN-BE) is a Pharmaceutical APIs and Formulations company trading at Rs 183.38 with a market capitalisation of Rs 918 crore. Analysts have set the Kopran share price target at Rs 220 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Kopran including sector tailwinds, key risks, and the bull and bear scenarios.
Click Here – Get Free Investment Predictions
Kopran Share Price Target 2026: Key Takeaways
- Kopran share price target 2026: Rs 220 (20% upside from CMP Rs 183.38)
- Bull case: Rs 265 | Bear case: Rs 145
- Ticker: KOPRAN-BE | Sector: Pharmaceutical APIs and Formulations | MCap: Rs 918 crore
- 52W range: Rs 128 to Rs 310 | PE: 15x
- Key catalyst: Q4 FY26 results and FY27 earnings recovery confirmation in 2026
- Key risk: FY27 earnings miss or sustained FII outflows from Indian equities
Kopran Company Overview
Kopran (NSE: KOPRAN-BE) is a Mumbai-based pharmaceutical company manufacturing APIs, fine chemicals, and formulations for domestic and regulated export markets, with a focus on macrolide antibiotics and specialty APIs. At CMP Rs 183.38 against a 52 week range of Rs 128 to Rs 310, the stock is trading at a meaningful discount to its 52 week high. The trailing PE is 15x and the Rs 220 analyst target implies approximately 20 percent upside from current levels. Compared to peers in pharma APIs like Divi’s Laboratories and Laurus Labs, Kopran is positioned as a potential re-rating candidate on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | KOPRAN-BE |
| Sector | Pharmaceutical APIs and Formulations |
| CMP (2026) | Rs 183.38 |
| 52 Week High | Rs 310 |
| 52 Week Low | Rs 128 |
| Market Cap | Rs 918 crore |
| Trailing PE | 15x |
| 12-Month Analyst Target | Rs 220 |
| Bull Case Target | Rs 265 |
| Bear Case Target | Rs 145 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Why Is the Kopran Share Price Target Set at Rs 220 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Kopran share price target of Rs 220 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating. Until FY27 PAT delivery is confirmed, the Rs 220 price objective represents a base case with execution risk attached.
Structural Sector Tailwinds in Pharmaceutical APIs and Formulations
The Pharmaceutical APIs and Formulations sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Kopran’s position among peers in pharma APIs like Divi’s Laboratories and Laurus Labs creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 265 bull case to materialise, making sector monitoring essential for investors tracking this stock.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Kopran, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 220 analyst consensus. This rate environment is a tailwind across the Pharmaceutical APIs and Formulations space.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Kopran’s Pharmaceutical APIs and Formulations operations. Policy support increases the probability of Kopran achieving its FY27 earnings targets, which in turn supports the Rs 220 price objective set by analysts for 2026.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Kopran is positioned as a beneficiary of institutional reallocation into mid-cap and small-cap Indian stocks. Sustained FII inflow is a necessary condition for re-rating the stock toward the Rs 265 bull case scenario.
Kopran Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Kopran Share Price Target
Near-term support for Kopran is anchored near the 52 week low of Rs 128. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a key reference while awaiting the FY27 earnings confirmation that would strengthen the case for the full price objective of Rs 220.
12-Month Kopran Share Price Target 2026
The 12-month Kopran share price target 2026 is Rs 220, implying approximately 20 percent upside from CMP Rs 183.38. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Investors can track live price movement on NSE under the ticker KOPRAN-BE to assess progress toward this target.
Long Term Kopran Share Price Target: FY27 to FY28
The long term Kopran share price target for the FY27 to FY28 period is Rs 265 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in pharma APIs like Divi’s Laboratories and Laurus Labs, and sustained institutional buying are the three conditions that need to align for the stock to reach the Rs 265 level over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Kopran in 2026
Bull Case Kopran Share Price Target: Rs 265
The bull case Kopran share price target of Rs 265 materialises when FY27 earnings beat analyst estimates, Pharmaceutical APIs and Formulations tailwinds accelerate beyond consensus, and FII flows return strongly to Indian equities. Under this scenario, Kopran re-rates toward higher peer multiples, making Rs 265 achievable within FY28. The current gap between CMP Rs 183.38 and Rs 265 represents approximately 45 percent potential upside.
Bear Case Kopran Share Price Target: Rs 145
The bear case Kopran share price target of Rs 145 materialises if FY27 earnings disappoint, management guides below expectations, or sustained FII outflows depress the broader mid-cap market. Under this scenario, the stock risks testing the 52 week low support near Rs 128, and investors should reassess the investment thesis before adding more capital.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 265 | FY27 earnings beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 220 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 145 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Kopran 2026 Price Objective
Global Macro and US Tariff Headwinds
The prolonged tariff tension triggered by the US reciprocal tariff announcement in 2026 has reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains the most prominent macro risk to the Kopran share price target of Rs 220 and could push the stock toward the bear case of Rs 145.
FY27 Earnings Miss and Guidance Risk
Any FY27 earnings miss or downward guidance revision by Kopran’s management would compress valuation multiples. This is the most direct company-specific risk to the Rs 220 analyst price objective. Investors should monitor quarterly results and management commentary closely, especially any signals about demand environment, pricing power, or margin compression in the Pharmaceutical APIs and Formulations segment.
Competitive Intensity Among Pharmaceutical APIs and Formulations Peers
Intensifying competition from peers in pharma APIs like Divi’s Laboratories and Laurus Labs could compress Kopran’s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory that underpins the Rs 220 analyst target truly is, particularly as new entrants and imports from China disrupt established market structures.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level operational improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns significantly. Investors should size positions carefully and maintain stop losses to protect capital if the broader market de-rating continues through FY27.
How to Invest in Kopran: A Step-by-Step Approach
Check the Univest Screener for live data
Before considering any investment based on the Kopran share price target of Rs 220, review the company’s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Pharmaceutical APIs and Formulations sector demand and competition.
Open a Demat and trading account with a SEBI registered stockbroker to trade Kopran (NSE: KOPRAN-BE) with regulatory protection. Complete KYC, and before executing any order, study the competitive landscape among peers in pharma APIs like Divi’s Laboratories and Laurus Labs to assess whether Kopran’s competitive position justifies the Rs 220 valuation.
Plan your entry using technical and fundamental triggers. The 52 week low of Rs 128 acts as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.
Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio. This is especially important in the Pharmaceutical APIs and Formulations space where sectoral cycles, regulatory changes, and commodity price swings can amplify volatility beyond initial expectations.
Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Kopran’s live share price and receive daily stock recommendations from SEBI registered analysts.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Kopran Share Price Target 2026
What is the Kopran share price target for 2026?
Ans. The Kopran share price target 2026 is Rs 220, implying approximately 20 percent upside from CMP Rs 183.38. The bull case estimate is Rs 265 and the bear case is Rs 145.
What was the Kopran share price target for 2025?
Ans. The 2025 price target for Kopran was based on FY26 earnings projections. The current 2026 analyst consensus stands at Rs 220, reflecting FY27 growth potential from CMP Rs 183.38.
Is Kopran a good investment at Rs 183.38?
Ans. At Rs 183.38, Kopran offers potential upside toward Rs 220 if FY27 earnings recover as projected. Whether the stock is a good buy depends on individual risk appetite, investment horizon, and portfolio goals. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Kopran share price target 2026?
Ans. Key risks to the Kopran share price target of Rs 220 include FY27 earnings miss, global tariff headwinds, sustained FII outflows, and competitive pressure in the Pharmaceutical APIs and Formulations sector. Monitoring quarterly results closely is essential.
What is the 52 week high and low of Kopran?
Ans. The 52 week high of Kopran is Rs 310 and the 52 week low is Rs 128. At CMP Rs 183.38, the stock is trading below its 52 week high and offers upside potential toward the Rs 220 analyst price objective.
What are the main growth catalysts for Kopran in 2026?
Ans. Primary growth catalysts for Kopran in 2026 include FY27 PAT recovery, Pharmaceutical APIs and Formulations sector tailwinds, RBI rate cuts reducing cost of capital, Union Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Kopran compare to its peers?
Ans. Kopran operates in Pharmaceutical APIs and Formulations alongside peers in pharma APIs like Divi’s Laboratories and Laurus Labs. At CMP Rs 183.38 with MCap Rs 918 crore, the company is positioned as a potential re-rating candidate toward the Kopran share price target of Rs 220 on FY27 earnings delivery.
What is the Kopran share price target for 2027?
Ans. The long-term Kopran share price target for FY27 to FY28 is Rs 265 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
